Published in AIDS on February 20, 2012
Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis (2015) 2.40
Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med (2015) 1.61
Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches. AIDS (2013) 1.34
Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs. Contraception (2014) 1.15
From exposures to population interventions: pregnancy and response to HIV therapy. Am J Epidemiol (2014) 1.13
Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS (2013) 1.11
Integrated strategies for combination HIV prevention: principles and examples for men who have sex with men in the Americas and heterosexual African populations. J Acquir Immune Defic Syndr (2013) 1.09
Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Hum Reprod (2014) 0.98
Preventing HIV infection in women. J Acquir Immune Defic Syndr (2013) 0.95
Pregnancy and contraceptive use among women participating in an HIV prevention trial in Tanzania. Sex Transm Infect (2012) 0.94
Changes in genital tract immune cell populations after initiation of intrauterine contraception. Am J Obstet Gynecol (2014) 0.93
Population-level impact of hormonal contraception on incidence of HIV infection and pregnancy in women in Durban, South Africa. Bull World Health Organ (2012) 0.90
An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS (2016) 0.88
Contraceptive methods and risk of HIV acquisition or female-to-male transmission. Curr HIV/AIDS Rep (2014) 0.88
Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting. AIDS Behav (2015) 0.85
Living with uncertainty: acting in the best interests of women. AIDS Res Treat (2012) 0.84
Application of marginal structural models in pharmacoepidemiologic studies: a systematic review. Pharmacoepidemiol Drug Saf (2014) 0.83
Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. Contraception (2015) 0.82
17β-estradiol protects primary macrophages against HIV infection through induction of interferon-alpha. Viral Immunol (2014) 0.82
Contraceptive adherence among HIV-infected women in Malawi: a randomized controlled trial of the copper intrauterine device and depot medroxyprogesterone acetate. Contraception (2013) 0.82
The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with Mycobacterium tuberculosis. Infect Immun (2013) 0.82
Medroxyprogesterone acetate impairs human dendritic cell activation and function. Hum Reprod (2015) 0.81
Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial. PLoS One (2013) 0.81
Medical eligibility, contraceptive choice, and intrauterine device acceptance among HIV-infected women receiving antiretroviral therapy in Lilongwe, Malawi. Int J Gynaecol Obstet (2014) 0.80
Awareness and interest in intrauterine contraceptive device use among HIV-positive women in Cape Town, South Africa. Infect Dis Obstet Gynecol (2012) 0.79
Medroxyprogesterone acetate differentially regulates interleukin (IL)-12 and IL-10 in a human ectocervical epithelial cell line in a glucocorticoid receptor (GR)-dependent manner. J Biol Chem (2014) 0.78
Levonorgestrel in contraceptives and multipurpose prevention technologies: does this progestin increase HIV risk or interact with antiretrovirals? AIDS (2016) 0.78
Could misreporting of condom use explain the observed association between injectable hormonal contraceptives and HIV acquisition risk? Contraception (2016) 0.75
Hormonal Contraception and HIV/AIDS Transmission: Challenges for Zimbabwe's Reproductive Health Service Providers in Promoting Informed Contraception Choices. J Public Health Africa (2013) 0.75
Uptake of hormonal contraceptives and correlates of uptake in a phase III clinical trial in rural South Western Uganda. Reprod Health (2017) 0.75
Gender-Specific Combination HIV Prevention for Youth in High-Burden Settings: The MP3 Youth Observational Pilot Study Protocol. JMIR Res Protoc (2017) 0.75
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 7.93
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med (2008) 6.00
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis (2008) 3.98
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (2010) 3.90
Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis (2008) 3.31
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Microfluidics-based diagnostics of infectious diseases in the developing world. Nat Med (2011) 2.68
Microbicide acceptability research: current approaches and future directions. Soc Sci Med (2005) 2.54
Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis (2004) 2.29
Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS (2010) 2.23
Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS (2010) 2.17
Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis (2004) 2.03
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol (2002) 1.97
Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis (2002) 1.88
Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sex Transm Dis (2009) 1.73
Mobile device for disease diagnosis and data tracking in resource-limited settings. Clin Chem (2013) 1.72
Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS (2010) 1.68
Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses (2003) 1.68
Assessing the reporting of adherence and sexual activity in a simulated microbicide trial in South Africa: an interview mode experiment using a placebo gel. AIDS Behav (2011) 1.68
Acceptability of Carraguard vaginal gel use among Thai couples. AIDS (2006) 1.65
The association between Mycoplasma genitalium and HIV-1 acquisition in African women. AIDS (2012) 1.64
"Actual use" study of emergency contraceptive pills provided in a simulated over-the-counter manner. Obstet Gynecol (2003) 1.59
Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing. J Womens Health (Larchmt) (2005) 1.56
HIV infection and sexual behaviour in primary and secondary infertile relationships: a case--control study in Kigali, Rwanda. Sex Transm Infect (2010) 1.51
Microbicide clinical trial adherence: insights for introduction. J Int AIDS Soc (2013) 1.47
Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception (2007) 1.46
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2014) 1.36
Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. J Acquir Immune Defic Syndr (2013) 1.33
Epidemiological synergy of Trichomonas vaginalis and HIV in Zimbabwean and South African women. Sex Transm Dis (2010) 1.29
Combined impact of sexual risk behaviors for HIV seroconversion among women in Durban, South Africa: implications for prevention policy and planning. AIDS Behav (2011) 1.28
Fourteen-day safety and acceptability study of the universal placebo gel. Contraception (2006) 1.27
Determinants of prevalent HIV infection and late HIV diagnosis among young women with two or more sexual partners in Beira, Mozambique. PLoS One (2013) 1.27
The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS (2012) 1.26
Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen. Am J Obstet Gynecol (2006) 1.25
Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. J Acquir Immune Defic Syndr (2014) 1.23
HIV incidence remains high in KwaZulu-Natal, South Africa: evidence from three districts. PLoS One (2012) 1.23
Provision of antiretroviral therapy in South Africa: unique challenges and remaining obstacles. J Infect Dis (2007) 1.20
Novel strategies implemented to ensure high participant retention rates in a community based HIV prevention effectiveness trial in South Africa and Zimbabwe. Contemp Clin Trials (2009) 1.15
Acceptability of PrEP for HIV prevention among women at high risk for HIV. J Womens Health (Larchmt) (2010) 1.14
Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa. AIDS Res Ther (2007) 1.13
Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS One (2013) 1.11
The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. J Acquir Immune Defic Syndr (2015) 1.10
Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS (2015) 1.10
"We have our protector": misperceptions of protection against HIV among participants in a microbicide efficacy trial. Am J Public Health (2006) 1.09
Acceptability and use of the diaphragm and Replens lubricant gel for HIV prevention in Southern Africa. AIDS Behav (2009) 1.08
The relationship between age of coital debut and HIV seroprevalence among women in Durban, South Africa: a cohort study. BMJ Open (2012) 1.07
The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers. Virus Res (2006) 1.07
Living situation affects adherence to combination antiretroviral therapy in HIV-infected adolescents in Rwanda: a qualitative study. PLoS One (2013) 1.06
Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. J Acquir Immune Defic Syndr (2011) 1.06
Longitudinal analysis of HIV type 1 subtype C envelope sequences from South Africa. AIDS Res Hum Retroviruses (2007) 1.06
Patterns and predictors of adherence to diaphragm use in a phase III trial in sub-Saharan Africa: a trajectory analysis. J Acquir Immune Defic Syndr (2009) 1.05
Microbicides to prevent heterosexual transmission of HIV: ten years down the road. BETA (2002) 1.05
Geoadditive models to assess spatial variation of HIV infections among women in local communities of Durban, South Africa. Int J Health Geogr (2011) 1.05
Male circumcision for HIV prevention: clinical practices and attitudes among healthcare providers in South Africa and Zimbabwe. Sex Transm Dis (2012) 1.03
Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa. J Acquir Immune Defic Syndr (2007) 1.02
Increases in human papillomavirus detection during early HIV infection among women in Zimbabwe. J Infect Dis (2011) 1.01
Is vaginal washing associated with increased risk of HIV-1 acquisition? AIDS (2006) 1.01
The use of the diaphragm instead of condoms in a phase III diaphragm trial. AIDS Behav (2008) 1.00
Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda. PLoS One (2013) 1.00
Improved access increases postpartum uptake of contraceptive implants among HIV-positive women in Rwanda. Eur J Contracept Reprod Health Care (2009) 0.99
Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). PLoS One (2013) 0.99
Discontinuation of oral contraceptives and depot medroxyprogesterone acetate among women with and without HIV in Uganda, Zimbabwe and Thailand. Contraception (2010) 0.99
The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antivir Ther (2011) 0.98
Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials. Sex Transm Dis (2013) 0.98
Preventing copper intrauterine device removals due to side effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen. Hum Reprod (2006) 0.98
African women recently infected with HIV-1 and HSV-2 have increased risk of acquiring Neisseria gonorrhoeae and Chlamydia trachomatis in the Methods for Improving Reproductive Health in Africa trial. Sex Transm Dis (2011) 0.97
Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP. Dev World Bioeth (2013) 0.96
High-risk human papillomavirus is associated with HIV acquisition among South African female sex workers. Infect Dis Obstet Gynecol (2011) 0.96
Bacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis (2014) 0.96
Risk factors for incidence of sexually transmitted infections among women in South Africa, Tanzania, and Zambia: results from HPTN 055 study. Sex Transm Dis (2009) 0.96
User experiences and acceptability attributes of the diaphragm and lubricant gel in an HIV prevention trial in southern Africa. AIDS Care (2011) 0.95
Identifying appropriate IUD candidates in areas with high prevalence of sexually transmitted infections. Contraception (2006) 0.94
Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. J Acquir Immune Defic Syndr (2014) 0.94
Preventing unintended pregnancy among young women in Kenya: prospective cohort study to offer contraceptive implants. Contraception (2012) 0.94
Willingness of clinicians to integrate microbicides into HIV prevention practices in southern Africa. AIDS Behav (2012) 0.92
Antiretroviral therapy drug adherence in Rwanda: perspectives from patients and healthcare workers using a mixed-methods approach. AIDS Care (2013) 0.92
Carraguard acceptability among men and women in a couples study in Thailand. J Womens Health (Larchmt) (2010) 0.92
Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. J Infect Dis (2012) 0.92
Contraception use and effectiveness among women in a trial of the diaphragm for HIV prevention. Contraception (2011) 0.92
Vaginal practices among women at high risk of HIV infection in Uganda and Tanzania: recorded behaviour from a daily pictorial diary. PLoS One (2013) 0.92
Microbicide acceptability: insights for future directions from providers and policy makers. AIDS Educ Prev (2008) 0.91
Assessing and evaluating the combined impact of behavioural and biological risk factors for HIV seroconversion in a cohort of South African women. AIDS Care (2012) 0.90